BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price raised by Scotiabank from $86.00 to $95.00 in a report published on Thursday morning, Benzinga reports. Scotiabank currently has a sector perform rating on the biotechnology company’s stock.
Several other brokerages have also issued reports on BMRN. Sanford C. Bernstein upgraded shares of BioMarin Pharmaceutical from a market perform rating to an outperform rating and lifted their target price for the company from $94.00 to $110.00 in a research report on Tuesday, August 20th. Piper Sandler upped their target price on shares of BioMarin Pharmaceutical from $107.00 to $122.00 and gave the stock an overweight rating in a research report on Thursday. Truist Financial reduced their target price on BioMarin Pharmaceutical from $140.00 to $118.00 and set a buy rating on the stock in a research note on Thursday. Cantor Fitzgerald reaffirmed an overweight rating and set a $110.00 price target on shares of BioMarin Pharmaceutical in a research note on Monday, August 5th. Finally, Baird R W cut BioMarin Pharmaceutical from a strong-buy rating to a hold rating in a report on Friday, May 17th. Eight equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of Moderate Buy and a consensus target price of $106.10.
Check Out Our Latest Stock Analysis on BMRN
BioMarin Pharmaceutical Trading Down 1.2 %
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last announced its earnings results on Monday, August 5th. The biotechnology company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.39. The business had revenue of $712.03 million for the quarter, compared to analyst estimates of $660.51 million. BioMarin Pharmaceutical had a return on equity of 6.91% and a net margin of 9.91%. Equities research analysts forecast that BioMarin Pharmaceutical will post 2.35 earnings per share for the current fiscal year.
Hedge Funds Weigh In On BioMarin Pharmaceutical
Hedge funds and other institutional investors have recently modified their holdings of the company. Sanctuary Advisors LLC bought a new position in BioMarin Pharmaceutical during the 2nd quarter valued at approximately $1,783,000. Teachers Retirement System of The State of Kentucky raised its holdings in shares of BioMarin Pharmaceutical by 17.4% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 194,207 shares of the biotechnology company’s stock valued at $15,990,000 after acquiring an additional 28,837 shares in the last quarter. Novo Holdings A S lifted its stake in BioMarin Pharmaceutical by 8.9% in the second quarter. Novo Holdings A S now owns 490,000 shares of the biotechnology company’s stock worth $40,342,000 after acquiring an additional 40,000 shares during the period. NewEdge Advisors LLC lifted its stake in BioMarin Pharmaceutical by 3,931.5% in the second quarter. NewEdge Advisors LLC now owns 10,885 shares of the biotechnology company’s stock worth $896,000 after acquiring an additional 10,615 shares during the period. Finally, Creative Planning boosted its holdings in BioMarin Pharmaceutical by 4.6% in the second quarter. Creative Planning now owns 11,825 shares of the biotechnology company’s stock valued at $974,000 after acquiring an additional 524 shares in the last quarter. 98.71% of the stock is owned by institutional investors.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading
- Five stocks we like better than BioMarin Pharmaceutical
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Stock Market Sectors: What Are They and How Many Are There?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- What is Short Interest? How to Use It
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.